Setback to Novartis: Delhi HC Rejects Cross-Examination Request in Post-Grant Patent Dispute Susmita Roy26 Sept 2025 5:18 PM ISTNew Delhi: The Delhi High Court on Tuesday sharply criticised Novartis AG's belated attempt to cross-examine opponents' experts in a post-grant patent...
Novartis Loses India Patent on Heart Failure Drug Vymada Susmita Roy18 Sept 2025 4:00 PM ISTNew Delhi: In a major setback for Swiss drugmaker Novartis, the Indian Patent Office (IPO) has cancelled the patent for its heart failure drug Vymada...
Novartis, Monte Rosa Therapeutics join hands for Degraders to treat Immune-mediated diseases Ruchika Sharma16 Sept 2025 12:15 PM ISTBoston: Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based...
Novartis to buy Tourmaline Bio for USD 1.4 billion Ruchika Sharma9 Sept 2025 2:30 PM ISTBasel: Novartis has announced that it has entered into an agreement to acquire Tourmaline Bio, Inc., a New York-based, publicly traded...
Novartis, Argo Biopharma expand strategic alliance with USD 5.2 billion Cardiovascular drugs deal Ruchika Sharma4 Sept 2025 12:13 PM ISTShanghai: Argo Biopharmaceutical Co., Ltd., a clinical-stage biotechnology company focused on developing next-generation siRNA therapeutics, has...
Novartis, Arrowhead strike upto USD 2 billion deal for neuromuscular therapy license Ruchika Sharma4 Sept 2025 10:30 AM ISTUnder the terms of the agreement, Novartis will receive an exclusive worldwide license to research, develop, manufacture, and commercialize ARO-SNCA.
Eli Lilly appoints Vivek Jha as Sr Director - Commercial Strategy, AI & Transformation within the Global Commercialization Capabilities, Innovation organization Ruchika Sharma3 Sept 2025 5:34 PM ISTEli Lilly and Company has appointed Vivek Jha as Leader (Senior Director) - Commercial Strategy, AI & Transformation within the Global...
Novartis Leqvio shows statistically significant, clinically meaningful early LDL-C goal achievement with less muscle pain Ruchika Sharma2 Sept 2025 12:25 PM ISTBasel: Novartis has announced positive results from V-DIFFERENCE, a Phase IV study evaluating Leqvio (inclisiran) compared to placebo, both...
Eris Lifesciences Slapped Rs 17 Crore GST Notice Over Novartis Zomelis Deal Farhat Nasim27 Aug 2025 10:00 AM ISTNew Delhi: Eris Lifesciences Limited has disclosed that it has received a show cause-cum-demand notice amounting to Rs16.84 crore from the Directorate...
Novartis ianalumab Phase III trial meets primary endpoint in immune thrombocytopenia Ruchika Sharma17 Aug 2025 2:00 PM ISTBasel: Novartis has announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with...
FDA Approves Inclisiran as First-Line LDL-C Treatment Without Statins Dr. Kamal Kant Kohli8 Aug 2025 9:15 AM ISTThe FDA has approved inclisiran (Leqvio) for first-line use in lowering LDL cholesterol, even without combining it with statins, according to...
Novartis eyes Avidity Biosciences in potential takeover: Report Ruchika Sharma7 Aug 2025 3:13 PM ISTSwiss pharmaceutical giant Novartis is exploring a potential acquisition of U.S. biotech firm Avidity Biosciences, according to a report by the...
